Search
BW-A 58C
go.drugbank.com/drugs/DB06740ExperimentalBW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsAmbroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalAmbroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several p...
Mixtures: EBROMIN-PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDesoxycorticosterone acetate
go.drugbank.com/drugs/DB06780ApprovedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDifluprednate
go.drugbank.com/drugs/DB06781ApprovedInvestigationalDifluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or diflu...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exa...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnA direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRoxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOspemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Synonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigationalIloperidone is a benzisoxazole and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. It is considered to be a second-generation antipsychotic drug with multiple receptor binding profile, although it shows...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates